Literature DB >> 12140335

Ribozyme suppression of endogenous thyroid hormone receptor activity in Xenopus laevis cells.

Wayland Lim1, J David Furlow.   

Abstract

Xenopus laevis is an excellent model for thyroid hormone (T3)-regulated gene expression. T3 initiates two drastically different pathways during metamorphosis: death of larval tissues and growth of adult tissues. The role that each T3 receptor (TR) isotype, alpha and beta, plays in metamorphosis is uncertain. The X.laevis tetraploid genome limits experiments to overexpression, misexpression and dominant negative studies. Ribozymes offer an alternative by suppressing gene activity through specific mRNA reduction. It has been suggested that ribozymes will not work in X.laevis because of the organism's intracellular environment and body temperature. In this study, we show that hammerhead ribozymes are active in vitro against transcribed TRbeta message and in vivo against a TRbeta-luciferase fusion protein. We next show that TRbeta-targeted ribozymes can inhibit T3-induced transcription of a reporter gene in cultured X.laevis cells, using T3 response elements from two T3-responsive transcription factor genes. One has early expression kinetics in response to T3 and is proposed to be TRalpha regulated whereas the other has intermediate induction kinetics and thus may be partially TRbeta regulated. Therefore, ribozymes are a potentially valuable tool for overcoming the limitations in this system for examining gene function in X.laevis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12140335      PMCID: PMC137085          DOI: 10.1093/nar/gkf461

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  25 in total

1.  Diverse developmental programs of Xenopus laevis metamorphosis are inhibited by a dominant negative thyroid hormone receptor.

Authors:  A M Schreiber; B Das; H Huang; N Marsh-Armstrong; D D Brown
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-21       Impact factor: 11.205

2.  Ribozymes correctly cleave a model substrate and endogenous RNA in vivo.

Authors:  S K Saxena; E J Ackerman
Journal:  J Biol Chem       Date:  1990-10-05       Impact factor: 5.157

3.  In vitro and in vivo analysis of the regulation of a transcription factor gene by thyroid hormone during Xenopus laevis metamorphosis.

Authors:  J D Furlow; D D Brown
Journal:  Mol Endocrinol       Date:  1999-12

4.  Xenopus laevis alpha and beta thyroid hormone receptors.

Authors:  Y Yaoita; Y B Shi; D D Brown
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

5.  Simple RNA enzymes with new and highly specific endoribonuclease activities.

Authors:  J Haseloff; W L Gerlach
Journal:  Nature       Date:  1988-08-18       Impact factor: 49.962

6.  Regulation of thyroid hormone receptor isoforms in physiological and pathological cardiac hypertrophy.

Authors:  K Kinugawa; K Yonekura; R C Ribeiro; Y Eto; T Aoyagi; J D Baxter; S A Camacho; M R Bristow; C S Long; P C Simpson
Journal:  Circ Res       Date:  2001-09-28       Impact factor: 17.367

7.  Cleavage of AML1/MTG8 by asymmetric hammerhead ribozymes.

Authors:  M Szyrach; F E Münchberg; H Riehle; A Nordheim; J Krauter; S Nagel; G Heil; O Heidenreich
Journal:  Eur J Biochem       Date:  2001-06

Review 8.  The mechanism of action of thyroid hormones.

Authors:  J Zhang; M A Lazar
Journal:  Annu Rev Physiol       Date:  2000       Impact factor: 19.318

9.  The thyroid hormone receptor-beta-selective agonist GC-1 differentially affects plasma lipids and cardiac activity.

Authors:  S U Trost; E Swanson; B Gloss; D B Wang-Iverson; H Zhang; T Volodarsky; G J Grover; J D Baxter; G Chiellini; T S Scanlan; W H Dillmann
Journal:  Endocrinology       Date:  2000-09       Impact factor: 4.736

10.  The homeobox gene, Xanf-1, can control both neural differentiation and patterning in the presumptive anterior neurectoderm of the Xenopus laevis embryo.

Authors:  G V Ermakova; E M Alexandrova; O V Kazanskaya; O L Vasiliev; M W Smith; A G Zaraisky
Journal:  Development       Date:  1999-10       Impact factor: 6.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.